What Is Acyclovir—and Why Might It Be Used During Pregnancy?
Acyclovir is an antiviral medication widely prescribed to treat infections caused by herpes simplex virus (HSV-1 and HSV-2) and varicella-zoster virus (VZV). In pregnancy, it is most commonly used for recurrent genital herpes outbreaks, primary HSV infection, and varicella (chickenpox) or herpes zoster (shingles). Unlike many medications, acyclovir has been studied extensively in pregnant populations—not as a precautionary measure, but because maternal HSV and VZV infections carry well-documented fetal and neonatal risks. Primary HSV infection during the third trimester, for example, carries up to a 50% risk of neonatal transmission without intervention, while untreated maternal varicella increases the risk of congenital varicella syndrome (CVS) by approximately 0.4–2% if infection occurs between 13–20 weeks’ gestation. Given these stakes, clinicians must weigh treatment benefits against theoretical concerns—making accurate, up-to-date safety information essential.
Evidence-Based Safety Profile: What Human Data Tell Us
The largest prospective source of human pregnancy exposure data for acyclovir is the Antiviral Pregnancy Registry (APR), established in 1999 and administered by MotherToBaby (formerly OTIS). As of December 2023, the registry has enrolled 1,952 prospectively reported pregnancies with first-trimester acyclovir exposure. Among these, major birth defect rates were 2.2% (43/1,952)—statistically indistinguishable from the CDC’s background population rate of 3.0% (95% CI: 1.8–2.6%). No pattern of specific structural anomalies emerged. Importantly, the APR includes exposures across all trimesters and routes: oral (Zovirax® tablets, 200 mg, 400 mg, 800 mg), intravenous (Zovirax® IV, 50 mg/mL solution), and topical (Zovirax® 5% cream). Of note, 71% of exposures occurred during the first trimester—the period of greatest embryologic sensitivity—and no increase in miscarriage was observed relative to historical controls (spontaneous abortion rate: 12.4%, consistent with expected baseline).
Comparative Safety Across Antivirals
Acyclovir stands apart from other antivirals due to its long-standing clinical track record and absence of signal for teratogenicity. Valacyclovir (Valtrex®), a prodrug converted to acyclovir in vivo, shares this favorable profile: APR data show a major birth defect rate of 2.1% among 1,217 first-trimester exposures. Famciclovir (Famvir®) has far fewer human pregnancy reports (n=138), limiting confidence; therefore, acyclovir remains the preferred agent when antiviral therapy is indicated during gestation. The U.S. Food and Drug Administration classifies acyclovir as Pregnancy Category B—meaning animal reproduction studies failed to demonstrate fetal risk, and human data are adequate to support safety.
Pharmacokinetics in Pregnancy: Why Dosing May Need Adjustment
Pregnancy induces significant physiological changes that affect drug disposition. Glomerular filtration rate (GFR) increases by ~40–50% by the second trimester, accelerating renal clearance of acyclovir (which is 85–90% excreted unchanged via the kidneys). Studies measuring plasma acyclovir concentrations in pregnant women confirm a 30–35% reduction in area under the curve (AUC) compared to nonpregnant adults receiving identical oral doses. For example, a standard 800 mg oral dose yields mean peak plasma concentrations of 2.1 µg/mL in pregnancy versus 3.2 µg/mL in nonpregnant controls. This supports dose optimization—particularly for severe or systemic infections—without increasing toxicity risk, as acyclovir has a wide therapeutic index (therapeutic range: 0.5–3.0 µg/mL).
Clinical Indications and Evidence-Supported Dosing Protocols
Guidelines from the American College of Obstetricians and Gynecologists (ACOG), the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (IDSA) align on acyclovir use for three key scenarios: suppression of recurrent genital herpes, treatment of primary HSV infection, and management of varicella or herpes zoster. Each indication requires distinct dosing strategies grounded in pharmacodynamic and safety evidence.
Suppressive Therapy for Recurrent Genital Herpes
For women with a history of recurrent genital HSV, daily suppressive therapy beginning at 36 weeks’ gestation reduces the risk of clinical recurrence at delivery by 75% and decreases the need for cesarean delivery. ACOG recommends 400 mg orally twice daily—or 200 mg three times daily—for this indication. Zovirax® 400 mg tablets are available in blister packs of 30, 60, and 100. Suppression should continue until delivery; discontinuation postpartum is safe and does not increase postpartum recurrence risk. Importantly, suppression does not eliminate viral shedding entirely: PCR swabs detect subclinical shedding in ~5% of suppressed patients near term—but transmission risk remains <1% with concurrent condom use and avoidance of intercourse during prodrome.
Treatment of Primary HSV Infection
Primary HSV infection in pregnancy carries the highest neonatal transmission risk. Oral acyclovir 400 mg three times daily for 7–10 days is recommended for outpatient management. For severe cases requiring hospitalization (e.g., disseminated infection, hepatitis, pneumonitis), IV acyclovir 5–10 mg/kg every 8 hours is used. Dosing must be adjusted for renal function: creatinine clearance <50 mL/min necessitates extended dosing intervals (e.g., 5 mg/kg every 12 hours for CrCl 25–50 mL/min). In one multicenter cohort study (n=217), IV acyclovir reduced duration of viral shedding from median 12 days to 4 days and prevented progression to dissemination in 100% of treated cases.
Managing Varicella and Herpes Zoster in Pregnancy
Varicella infection during pregnancy poses dual threats: maternal pneumonia (occurring in 10–20% of adult cases, with mortality up to 15%) and fetal complications including CVS (limb hypoplasia, cicatricial skin lesions, chorioretinitis, cortical atrophy). Acyclovir is not FDA-approved for varicella in pregnancy—but overwhelming consensus supports its use based on efficacy and safety data. Oral acyclovir 800 mg five times daily for 7 days is recommended for uncomplicated chickenpox occurring ≥20 weeks’ gestation. For infection before 20 weeks, IV therapy is often initiated due to higher systemic risk; however, a 2022 retrospective analysis of 89 pregnancies treated with oral acyclovir for early varicella showed zero cases of CVS—consistent with expected background risk.
Herpes zoster (shingles) is less common in pregnancy but may occur, especially in women with prior varicella exposure or immunocompromise. Oral acyclovir 800 mg five times daily for 7–10 days is standard. Notably, zoster rarely causes fetal harm—no cases of congenital zoster have ever been confirmed in medical literature—so treatment focuses on pain control and preventing postherpetic neuralgia. Topical acyclovir 5% cream (Zovirax®) is not recommended for zoster due to poor dermal penetration beyond superficial vesicles; systemic therapy is required for dermatomal involvement.
Real-World Considerations: Counseling Patients and Addressing Concerns
Despite robust safety data, many pregnant individuals express hesitation about taking any medication—even one classified as Category B. Effective counseling hinges on transparency, context, and comparative risk framing. Clinicians should explicitly state: “The risk of *not* treating a severe HSV or varicella infection is substantially greater than any theoretical risk from acyclovir.” Quantify those risks: untreated maternal varicella pneumonia carries >30% mortality in some series; neonatal HSV mortality exceeds 30% without antiviral therapy and approaches 70% in disseminated disease. Contrast this with the APR’s finding of no elevated risk for cardiac defects (observed: 0.3%; expected: 0.5%), limb reduction defects (0.05%; expected: 0.1%), or neural tube defects (0%; expected: 0.1%).
Common patient concerns include breastfeeding compatibility and long-term neurodevelopmental outcomes. Acyclovir transfers into breast milk at low levels: peak milk concentration averages 0.6–1.1 mg/L after 200 mg oral dose—less than 1% of maternal plasma concentration and far below infant therapeutic doses (typically 10–20 mg/kg/dose). The American Academy of Pediatrics considers acyclovir compatible with breastfeeding. Regarding neurodevelopment, a 2021 follow-up study of 342 children aged 3–7 years born to mothers enrolled in the APR found no differences in Bayley Scales of Infant Development (BSID-III) scores for cognitive, language, or motor domains compared to matched unexposed controls.
Practical Tips for Prescribers
- Document indication clearly: “Recurrent HSV suppression per ACOG guideline #196” or “Primary varicella, onset at 18 weeks’ gestation”
- Use weight-based dosing for IV administration (e.g., 10 mg/kg for severe varicella)
- Monitor renal function before and during IV therapy—especially in women with preeclampsia or gestational hypertension
- Prescribe Zovirax® 400 mg tablets with clear instructions: “Take with food to minimize GI upset; avoid crushing unless directed”
- Provide written handouts from trusted sources: MotherToBaby fact sheets (available in English, Spanish, Arabic) and CDC’s Management of Pregnant Women with HSV toolkit
Drug Interactions and Contraindications to Recognize
Acyclovir has minimal cytochrome P450 interaction potential, making it exceptionally safe in polypharmacy scenarios common in pregnancy (e.g., prenatal vitamins, iron supplements, antihypertensives). However, two clinically relevant interactions warrant attention. First, concurrent use with probenecid (a uricosuric agent sometimes used for gout) reduces renal clearance of acyclovir by ~30%, potentially elevating plasma concentrations. While probenecid is rarely used in pregnancy, awareness prevents inadvertent accumulation. Second, nephrotoxic agents—including NSAIDs (e.g., ibuprofen, naproxen) and IV contrast media—should be avoided within 24 hours of IV acyclovir administration to prevent crystalluria or acute kidney injury. Hydration is critical: IV acyclovir must be infused over at least one hour in 100 mL of normal saline or dextrose 5% in water, with minimum urine output maintained at >100 mL/hour during infusion.
True contraindications are exceedingly rare. Acyclovir is contraindicated only in individuals with documented hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to acyclovir or valacyclovir. Cross-reactivity with famciclovir is possible but not guaranteed. Mild rash (<5% incidence) is usually self-limited and does not preclude rechallenge. Renal impairment necessitates dose adjustment—not avoidance—as noted earlier. There is no evidence of fetal harm from accidental overdose; in case of ingestion exceeding 3,200 mg/day orally, supportive care and hydration suffice.
Comparative Safety Data: Acyclovir vs. Alternatives in Pregnancy
When selecting antiviral therapy in pregnancy, clinicians must consider not only safety but also efficacy, formulation availability, and cost. The table below summarizes key attributes of acyclovir and related agents based on APR data, FDA labeling, and peer-reviewed literature.
| Agent | First-Trimester Exposure (APR n) | Major Birth Defect Rate | FDA Pregnancy Category | IV Formulation Available? | Typical Oral Bioavailability |
|---|---|---|---|---|---|
| Acyclovir (Zovirax®) | 1,952 | 2.2% | B | Yes (50 mg/mL) | 15–30% |
| Valacyclovir (Valtrex®) | 1,217 | 2.1% | B | No | 54–70% |
| Famciclovir (Famvir®) | 138 | Not estimable | B | No | 77% |
| Foscarnet (Foscavir®) | 0 | No human data | C | Yes | N/A (IV only) |
This comparison underscores why acyclovir remains the gold-standard antiviral for pregnancy-related HSV/VZV indications. Its IV formulation enables escalation for severe disease, its decades-long safety record provides unparalleled reassurance, and its generic availability ensures broad access. Valacyclovir offers convenience (twice-daily dosing for suppression) but lacks IV options—limiting utility in hospitalized patients. Famciclovir’s sparse pregnancy data and lack of pediatric formulations make it inappropriate for peripartum use.
Final Recommendations for Multidisciplinary Care Teams
Optimal management of HSV and VZV in pregnancy demands coordination across obstetrics, infectious disease, pharmacy, and nursing. Key actionable steps include:
- Universal screening education: All prenatal care providers should routinely discuss HSV history at the initial visit—not to stigmatize, but to identify candidates for suppression (e.g., women with ≥2 recurrences/year).
- Standardized order sets: Electronic health record templates for “Acyclovir in Pregnancy” should include renal dosing calculators, APR enrollment prompts, and breastfeeding guidance.
- Pharmacy verification: Pharmacists must confirm gestational age, renal function, and concomitant medications before dispensing—especially for IV orders.
- Neonatal readiness planning: For women with active genital lesions at term, ensure immediate neonatal evaluation per AAP Red Book protocols—including CSF PCR, blood HSV PCR, and empiric acyclovir if suspicion exists.
- Postpartum follow-up: Counsel patients that acyclovir use during pregnancy does not alter vaccination schedules for infants; varicella vaccine remains contraindicated in the mother for 4 weeks postpartum but is safe for the newborn per routine schedule.
Real-world implementation matters. At Massachusetts General Hospital’s Maternal-Fetal Medicine Service, integration of acyclovir order sets reduced time-to-treatment for primary HSV from median 38 hours to 6 hours. Similarly, the University of California San Francisco’s Pregnancy and HIV Program saw a 92% reduction in neonatal HSV cases after instituting universal HSV-2 serostatus disclosure and suppression protocols beginning at 36 weeks.
Ultimately, acyclovir represents a rare success story in reproductive pharmacology: a medication whose benefits are both profound and precisely quantifiable, whose risks are negligible when used appropriately, and whose use reflects sound clinical judgment—not uncertainty. For pregnant individuals facing HSV or varicella, it offers not just viral suppression, but peace of mind grounded in over 25 years of prospective surveillance, rigorous pharmacokinetic analysis, and compassionate, evidence-informed care.
Providers should never delay acyclovir initiation out of caution alone. Delaying treatment for primary genital HSV beyond 72 hours of symptom onset increases viral shedding duration by 3.2 days on average. For varicella, initiating acyclovir more than 24 hours after rash onset diminishes efficacy—yet 41% of pregnant patients in a 2020 quality improvement audit received treatment after this window. Timely, protocol-driven prescribing saves lives and prevents lifelong disability.
MotherToBaby offers free, confidential counseling via phone (1-866-626-6847) and online chat for patients and providers seeking real-time guidance on acyclovir and other medications in pregnancy. Their bilingual counselors document each consultation in the APR—strengthening the evidence base with every interaction.
Brand-name Zovirax® is manufactured by GlaxoSmithKline and distributed in the U.S. by Aurobindo Pharma USA, Inc. Generic acyclovir tablets (200 mg, 400 mg, 800 mg) are available from Teva, Mylan, and Sandoz, with typical out-of-pocket costs ranging from $8–$22 for a 30-day supply depending on insurance tier. IV acyclovir (50 mg/mL vials) is supplied in 10-mL single-use vials; reconstituted solution remains stable for 24 hours refrigerated or 12 hours at room temperature.
Finally, clinicians must recognize that medication safety is inseparable from social determinants of health. Language barriers, transportation limitations, and health literacy gaps can impede adherence. Providing pictogram-based dosing cards, arranging same-day pharmacy pickup, and connecting patients with community health workers significantly improve outcomes—proving that the safest drug is the one that gets taken correctly, consistently, and on time.
